ArticleHepatology international2026
Association of total and regional fat-to-muscle ratio with the risk of metabolic dysfunction-associated fatty liver disease and other chronic liver diseases.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Interorgan Crosstalk in MASLD: A Narrative Review.Biomedicines · 2026Review
- Comparison of the diagnostic performance of alanine aminotransferase and ultrasonography for discrimination of liver biopsy proven metabolic associated steatotic liver disease: a ROC curve analysis.BMC endocrine disorders · 2026Article
- Association of a novel Fat-Muscle-BMI Index (FMBI) with NAFLD, liver fibrosis, and atherosclerotic cardiovascular disease risk: a cross-sectional study in 1,592 Chinese adults.BMC gastroenterology · 2026Article
- Associations between novel triglyceride glucose and adiposity-related indices and risk of metabolic dysfunction-associated steatotic liver disease: the mediating role of biological aging and evidence from the UK Biobank.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundWe examined whether total and regional fat-to-muscle ratio (FMR) predicts incident metabolic dysfunction-associated steatotic liver disease (MASLD) and other chronic liver outcomes.
methodsAmong 356,833 UK Biobank participants (men: 168,784 [47.3%]; women: 188,049 [52.7%]; mean age 56.3 years), body composition was assessed by segmental bioelectrical impedance analysis (BIA), from which whole-body and regional (arm, leg, trunk) FMRs were derived and categorized into sex-specific tertiles. Tertile cutpoints (lower and upper) were: men-whole-body (0.309, 0.396), arm (0.264, 0.333), leg (0.254, 0.325), trunk (0.348, 0.453); women-whole-body (0.526, 0.679), arm (0.500, 0.692), leg (0.640, 0.778), trunk (0.462, 0.621). Cox proportional hazards models were applied. MRI subsets included liver proton density fat fraction (PDFF) (n = 32,191) and hepatic fibro-inflammation (iron-corrected T1 [cT1]) (n = 27,028).
resultsOver a median follow-up of 14.0 years, there were 4,404 MASLD, 1,392 cirrhosis, 947 liver-related mortality, and 147 HCC events. Comparing the highest (T3) versus the lowest (T1) tertile of FMR, MASLD risk increased in both sexes across whole-body and regional FMRs (HR 2.29-2.76), with the strongest associations for leg FMR in women (HR 2.95). For cirrhosis and liver-related mortality, T3 associations were mainly seen in men and were strongest for whole-body and trunk/arm FMR (HR 1.63-2.11), while women showed weak/null associations (HR 1.29-1.54). For HCC, T3 FMR was strongly associated in men (HR 3.03-4.71), while no clear associations were evident in women.
conclusionHigher total and regional FMR predicts MASLD and advanced liver outcomes with clear sex- and region-specific patterns.
Indexed as
Identifiers
41787001What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.